PRPH - ProPhase Labs, Inc.
0.286
0.016 5.420%
Share volume: 1,447,833
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$0.27
0.02
0.06%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-10-2024 | 08-11-2023 | 11-13-2023 | 11-13-2024 | 05-10-2024 | 08-14-2024 | 11-13-2024 | |
| Total revenue | 19.303 M | 13.217 M | 8.365 M | 3.499 M | 3.634 M | 2.474 M | 3.146 M | |
| Cost of revenue | 8.783 M | 6.769 M | 6.038 M | 6.555 M | 4.067 M | 2.950 M | 3.311 M | |
| Gross profit | 10.520 M | 6.448 M | 2.327 M | -3.056 M | -433.000 K | -476.000 K | -165.000 K | |
| -38.71% | -63.91% | -231.33% | 85.83% | -9.93% | 65.34% | |||
| Operating expenses | 9.645 M | 11.106 M | 8.805 M | 8.296 M | 7.865 M | 7.351 M | 7.772 M | |
| Selling general and admin | 9.501 M | 10.534 M | 8.377 M | 8.022 M | 7.593 M | 7.212 M | 7.650 M | |
| Research and development | 144.000 K | 572.000 K | 428.000 K | 274.000 K | 272.000 K | 139.000 K | 122.000 K | |
| Total expenses | 9.645 M | 11.106 M | 8.805 M | 8.296 M | 7.865 M | 7.351 M | 7.772 M | |
| 15.15% | -20.72% | -5.78% | -5.20% | -6.54% | 5.73% | |||
| Operating income | 875.000 K | -4.658 M | -6.478 M | -11.352 M | -8.298 M | -7.827 M | -7.937 M | |
| Ebit | 768.000 K | -4.650 M | -6.511 M | -11.210 M | -8.316 M | -7.797 M | -7.937 M | |
| Pretax income | 564.000 K | -4.914 M | -6.785 M | -11.665 M | -8.831 M | -8.440 M | -9.095 M | |
| -971.28% | 38.07% | 71.92% | -24.29% | -4.43% | 7.76% | |||
| Income tax | 14.000 K | -1.474 M | -1.644 M | -2.914 M | -2.566 M | -2.287 M | -2.508 M | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | 550.000 K | -3.440 M | -5.141 M | -8.751 M | -6.265 M | -6.153 M | -6.587 M | |
| -725.45% | -49.45% | -70.22% | 28.41% | 1.79% | -7.05% |
